Experimental Therapy

Biochemical pathways became targets

The programme associated with Elion and Hitchings compared how cells and pathogens used purines, essential components of nucleic acids. Researchers then synthesised related compounds intended to interrupt vulnerable pathways.

Leukemia treatment altered childhood prognosis

Purine analogues including 6-mercaptopurine became important components of combination therapy for childhood leukemia. They did not emerge from theory alone: synthesis, biological screening, animal work, clinical trials, dosing, and management of toxicity all shaped their use.

Immune suppression enabled transplantation

Azathioprine helped suppress rejection after organ transplantation. The drug's history connects a chemical programme to surgeons, immunologists, donors, recipients, and the difficult ethics of allocating organs and balancing infection against rejection.

One approach reached many diseases

Related team research contributed to treatments for gout, malaria, and infection. Later work supported acyclovir, an antiviral drug that selectively interfered with herpesvirus replication and demonstrated that viral infections could be treated without simply destroying host cells.

Method mattered more than one molecule

The 1988 Nobel Prize recognised Elion, Hitchings, and James Black for principles of drug treatment. Their work helped establish a more systematic relationship among biochemistry, compound design, screening, and clinical use.

Industrial Science

A laboratory career grew despite blocked routes

Elion graduated from Hunter College and earned a master's degree at New York University while working. Employers repeatedly denied her research opportunities because she was a woman. Wartime demand for chemists opened positions but did not erase discrimination.

She joined Hitchings at Burroughs Wellcome in 1944. Rather than completing a doctorate under rules that would have required her to abandon full-time research, she remained in the laboratory and gained responsibility across chemistry, microbiology, pharmacology, immunology, and virology.

By 1967 she led the Department of Experimental Therapy. Her “mini-institute” depended on collaboration across specialties, complicating accounts that attach each medicine to a single name.

Credit and Access

Therapeutic success creates new historical questions

Elion's recognition challenged barriers facing women in science, but individual achievement did not by itself equalise hiring, promotion, pay, or authorship. Her career became possible within a commercial company able to fund long programmes and control resulting products.

Drug histories continue after approval. Manufacturing, patents, price, monitoring, resistance, and global distribution determine who benefits. Rational design can produce a powerful molecule without guaranteeing rational access.

Across the collection

Continue from Elion

Pharmacy

Connect drug design to production, regulation, safety, and access.

Cancer treatment

Follow combination therapy, trials, toxicity, and changing survival.